Regencell Bioscience Holdings Limited

RGC

$6.48

+2.69%

N/A+$0.17

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, ...

Fundamental Analysis of RGC

Key Strengths

Focused therapeutic niche: TCM-based approach targeting neurocognitive disorders (ADHD/ASD), which can enable clearer market positioning if clinical/commercial outcomes materialize

Liquidity appears adequate near term (current ratio 1.415; quick ratio 1.415), reducing immediate refinancing pressure versus companies with thinner balances

Risk Factors

No demonstrated trailing profitability: negative ROA/ROE/ROIC and essentially unusable margin/earnings metrics in the provided TTM dataset

Negative/insufficient cash generation: free-cash-flow and operating cash-flow signals are weak (large negative EV-to-cash-flow and negative cash flow metrics), increasing dependence on continued funding

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-456.34x

Current Ratio1.42

Efficiency

ROE-231.87%

ROA-233.91%

Fundamental Analysis of RGC

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is a Hong Kong-based biotechnology company focused on Traditional Chinese Medicine (TCM) solutions aimed at neurocognitive disorders, particularly ADHD and autism spectrum disorder (ASD). Fundamental assessment from the provided trailing (TTM) dataset indicates the business is not yet demonstrating operating profitability or positive returns on capital. Reported TTM profitability metrics are effectively non-existent in the dataset (e.g., gross/operating/net margin and EBITDA margin shown as 0), while returns are materially negative: ROA is -2.339%, operating ROA is -1.627%, ROE is -2.319%, and ROIC is -4.442% (and other capital-employment measures are similarly negative). This profile is consistent with a developmental-stage or investment-heavy biotech, where revenue exists but scaling and/or commercialization economics have not translated into sustained earnings power. Valuation signals are also distorted by losses. The trailing P/E is negative (priceToEarningsRatioTTM approximately -373), and earnings yield and free-cash-flow yield are negative as well, implying that standard earnings-based valuation frameworks are not currently reliable. Cash-flow metrics also look weak: enterprise value to operating cash flow and free cash flow are presented as large negative values (evToOperatingCashFlowTTM and evToFreeCashFlowTTM are both -1012.53). Despite this, the company shows moderate liquidity with a current ratio of 1.415 and a quick ratio of 1.415, suggesting near-term balance-sheet resilience. On leverage, debt-to-equity is 0.317 and debt-to-assets is 0.128, with a net debt-to-EBITDA measure of 0.28; however, interest coverage is effectively 0 and the dataset shows weak coverage ratios, meaning debt service depends heavily on future operating improvement. The stock’s beta (1.493) implies higher market sensitivity and volatility. Given negative profitability, negative cash-generation, and reliance on successful future commercialization/R&D progress, the fundamental setup is high-risk. For long-term investors, the key question is whether the company can convert its TCM pipeline/clinical and commercialization efforts into scalable revenue with improving margins and cash flow. Until those milestones are evidenced in financial statements, the fundamental bias remains cautious.

Key Strengths of RGC

Focused therapeutic niche: TCM-based approach targeting neurocognitive disorders (ADHD/ASD), which can enable clearer market positioning if clinical/commercial outcomes materialize
Liquidity appears adequate near term (current ratio 1.415; quick ratio 1.415), reducing immediate refinancing pressure versus companies with thinner balances
Moderate leverage profile on balance-sheet ratios (debt-to-equity ~0.317; debt-to-assets ~0.128), suggesting debt is not the dominant risk driver in the provided snapshot
Regulatory/market intent is clearly directed at commercialization (“market leader” goal for best treatment of ADHD/ASD), supporting potential execution focus
Small-cap biotech characteristics may offer upside if development and commercialization milestones are achieved (high beta indicates potential for strong re-rating upon progress)

Risk Factors of RGC

No demonstrated trailing profitability: negative ROA/ROE/ROIC and essentially unusable margin/earnings metrics in the provided TTM dataset
Negative/insufficient cash generation: free-cash-flow and operating cash-flow signals are weak (large negative EV-to-cash-flow and negative cash flow metrics), increasing dependence on continued funding
Valuation metrics are distorted due to losses (negative P/E and negative earnings yield), making intrinsic valuation harder and increasing downside risk if expectations reset
High volatility and uncertainty risk (beta 1.493; third-party/market references indicate notable price volatility), typical for development-stage biotech
Interest and coverage metrics are effectively zero/weak (interest coverage ~0 and coverage ratios negative), suggesting earnings deterioration would quickly pressure credit/financing flexibility
R&D and clinical/commercial execution risk: outcomes in ADHD/ASD therapeutics can be uncertain, and TCM scientific validation and scale-up may face additional scrutiny
Low financial data availability from provided statements (balance sheet/income statement/cash flow from Alpha sources are empty), limiting confidence in trend analysis and increases reliance on partial TTM ratios

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$3.21B

-456.3x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.32

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of RGC

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of RGC

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of RGC

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	1.415	—	—	Flat
Quick Ratio	—	1.415	—	—	Flat
Debt / Equity	—	0.317	—	—	Flat

Valuation of RGC

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-490.65x	—	—	Flat
P/B	—	8516.00x	—	—	Flat

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer